1291 results found
NHMRC-supported research at St Vincent’s Institute of Medical Research (SVI) has led to the development of bone cell biology as a field, defining the key bone cell types, their regulation, and interactions. This foundational work has had significant positive effects upon clinical practice, particularly in the treatment of osteoporosis, hypercalcaemia of malignancy, and osteogenic sarcoma. The research has contributed to the development of widely used therapeutics such as denosumab and has influenced global clinical practice. View the video on Discovery of RANK Ligand’s role in bone metabolism and the immune system to treat osteoporosis.
Questions and answers from the Ideas Grants 2024 peer reviewer webinar. Recorded 16 July 2024. A PDF version is available to download.
Fetal Alcohol Spectrum Disorder (FASD) is caused by prenatal alcohol exposure and is characterised by severe neurodevelopmental impairment, that may include intellectual disability, behavioural and other developmental problems.1,2 FASD causes a significant burden to individuals, the health care, education, and justice systems and society.1,2
This factsheet aims to support people to: understand the basics of DNA, genes and chromosomes; consider whether to get tested; understand the potential outcomes of the genetic testing process; and find more information and support.
Transcript for the Ideas Grants peer reviewer Q&A webinar. Recorded on Tuesday, 16 July 2024 1:00 pm - 3:00 pm (AEST).
The 46th biannual report
The 40th biannual report
Led by the CEO, our leadership and governance ensure NHMRC operates effectively and efficiently at all levels. This allows us to remain focused on the health care areas that matter most to Australia. Our leadership team has considerable experience in research strategy and programs, evidence-based medicine, research policy and translation, and corporate operations. We use their collective skills to develop strategic initiatives to improve Australian health and support health research.
The ME/CFS Scoping Survey was released by NHMRC on 21 February 2025 and was open for 9 weeks through to 27 April 2025. The survey was open to the public and was designed to gather insights from individuals with ME/CFS and related conditions (Long COVID, postural orthostatic intolerance syndrome (POTS) and fibromyalgia), carers, GPs and other healthcare professionals that provide care to people with ME/CFS and related conditions, researchers and consumer organisations. The purpose of the survey was to understand what stakeholders consider priorities for inclusion in the new Australian ME/CFS Clinical Practice Guidelines and to understand patient and healthcare professionals’ experiences of barriers to and/or enablers of care.The full report is available from the Downloads section.
The 45th biannual report
10 of the Best 2011 showcases 10 Australian health and medical research projects chosen from among the thousands of NHMRC funded medical research projects in Australia.
Guidelines and advice that have been rescinded or where NHMRC approval has expired.
The National Health and Medical Research Council (NHMRC) engages with health consumer and community groups to identify community representatives, consumers and/or carers to participate in our committees, peer review processes, guideline development and public consultation.
The NHMRC Complaints Policy sets out how NHMRC manages complaints about its activities, policies and decision-making.